orqr67

Property	Value
?:abstract	BackgroundIt is critical to understand whether infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent reinfection. MethodsWe investigated the incidence of SARS-CoV-2 PCR-positive results in seropositive and seronegative healthcare workers (HCWs) attending asymptomatic and symptomatic staff testing at Oxford University Hospitals, UK. Baseline antibody status was determined using anti-spike and/or anti-nucleocapsid IgG assays and staff followed for up to 30 weeks. We used Poisson regression to estimate the relative incidence of PCR-positive results and new symptomatic infection by antibody status, accounting for age, gender and changes in incidence over time. ResultsA total of 12219 HCWs participated and had anti-spike IgG measured, 11052 were followed up after negative and 1246 after positive antibody results including 79 who seroconverted during follow up. 89 PCR-confirmed symptomatic infections occurred in seronegative individuals (0.46 cases per 10,000 days at risk) and no symptomatic infections in those with anti-spike antibodies. Additionally, 76 (0.40/10,000 days at risk) anti-spike IgG seronegative individuals had PCR-positive tests in asymptomatic screening, compared to 3 (0.21/10,000 days at risk) seropositive individuals. Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]). Rate ratios were similar using anti-nucleocapsid IgG alone or combined with anti-spike IgG to determine baseline status. ConclusionsPrior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection. Further work is required to determine the long-term duration and correlates of post-infection immunity.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/12orqr67_hasAnnotation_C0205339> <https://research.tib.eu/covid-19/entity/12orqr67_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/12orqr67_hasAnnotation_C3714514> <https://research.tib.eu/covid-19/entity/12orqr67_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Lumley%2C_Sheila_F%3B_Stoesser%2C_Nicole_E%3B_Matthews%2C_Philippa_C%3B_Howarth%2C_Alison%3B_Hatch%2C_Stephanie_B%3B_Marsden%2C_Brian_D%3B_Cox%2C_Stuart%3B_James%2C_Tim%3B_Warren%2C_Fiona%3B_Peck%2C_Liam_J%3B_Ritter%2C_Thomas_G%3B_Toledo%2C_Zoe_de%3B_Warren%2C_Laura%3B_Axten%2C_David%3B_Cornall%2C_Richard_J%3B_Jones%2C_E_Yvonne%3B_Stuart%2C_David_I%3B_Screaton%2C_Gavin%3B_Ebner%2C_Daniel%3B_Hoosdally%2C_Sarah%3B_Chand%2C_Meera%3B_Group%2C_-_Oxford_University_Hospitals_Staff_Testing%3B_Crook%2C_Derrick_W%3B_Conlon%2C_Christopher_P%3B_Pouwels%2C_Koen_B%3B_Walker%2C_A_Sarah%3B_Peto%2C_Tim_EA%3B_Hopkins%2C_Susan%3B_Walker%2C_Tim_M%3B_Jeffery%2C_Katie%3B_Eyre%2C_David_W>
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.11.18.20234369>
?:doi	10.1101/2020.11.18.20234369
?:license	cc-by
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/12orqr67_HAS_C0003241_PREVENTS_C0205339> <https://research.tib.eu/covid-19/entity/12orqr67_HAS_C3714514_ASSOCIATED_WITH_C1624602>
?:source	MedRxiv; WHO
?:title	Antibodies to SARS-CoV-2 are associated with protection against reinfection
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#20234369
?:year	2020

Property

Value

?:abstract

BackgroundIt is critical to understand whether infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent reinfection. MethodsWe investigated the incidence of SARS-CoV-2 PCR-positive results in seropositive and seronegative healthcare workers (HCWs) attending asymptomatic and symptomatic staff testing at Oxford University Hospitals, UK. Baseline antibody status was determined using anti-spike and/or anti-nucleocapsid IgG assays and staff followed for up to 30 weeks. We used Poisson regression to estimate the relative incidence of PCR-positive results and new symptomatic infection by antibody status, accounting for age, gender and changes in incidence over time. ResultsA total of 12219 HCWs participated and had anti-spike IgG measured, 11052 were followed up after negative and 1246 after positive antibody results including 79 who seroconverted during follow up. 89 PCR-confirmed symptomatic infections occurred in seronegative individuals (0.46 cases per 10,000 days at risk) and no symptomatic infections in those with anti-spike antibodies. Additionally, 76 (0.40/10,000 days at risk) anti-spike IgG seronegative individuals had PCR-positive tests in asymptomatic screening, compared to 3 (0.21/10,000 days at risk) seropositive individuals. Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]). Rate ratios were similar using anti-nucleocapsid IgG alone or combined with anti-spike IgG to determine baseline status. ConclusionsPrior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection. Further work is required to determine the long-term duration and correlates of post-infection immunity.

is ?:annotates of